These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 10755499)

  • 21. E5 monoclonal immunoglobulin M antibody for the treatment of gram-negative sepsis.
    Olsen KM; Campbell GD
    DICP; 1991; 25(7-8):784-90. PubMed ID: 1949940
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Open randomized phase II trial of an extracorporeal endotoxin adsorber in suspected Gram-negative sepsis.
    Reinhart K; Meier-Hellmann A; Beale R; Forst H; Boehm D; Willatts S; Rothe KF; Adolph M; Hoffmann JE; Boehme M; Bredle DL;
    Crit Care Med; 2004 Aug; 32(8):1662-8. PubMed ID: 15286541
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of the efficacy, safety, and therapeutic usage of HA-1A and E5 in the treatment of gram-negative sepsis.
    Quintiliani R; Cooper B; Maderazo E; Nightingale C
    Hosp Formul; 1992 Jan; 27(1):49-52, 54, 57-60. PubMed ID: 10116116
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomized, placebo-controlled trial of the anti-tumor necrosis factor antibody fragment afelimomab in hyperinflammatory response during severe sepsis: The RAMSES Study.
    Reinhart K; Menges T; Gardlund B; Harm Zwaveling J; Smithes M; Vincent JL; Tellado JM; Salgado-Remigio A; Zimlichman R; Withington S; Tschaikowsky K; Brase R; Damas P; Kupper H; Kempeni J; Eiselstein J; Kaul M
    Crit Care Med; 2001 Apr; 29(4):765-9. PubMed ID: 11373466
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: results of a phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trial.
    Opal S; Laterre PF; Abraham E; Francois B; Wittebole X; Lowry S; Dhainaut JF; Warren B; Dugernier T; Lopez A; Sanchez M; Demeyer I; Jauregui L; Lorente JA; McGee W; Reinhart K; Kljucar S; Souza S; Pribble J;
    Crit Care Med; 2004 Feb; 32(2):332-41. PubMed ID: 14758145
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of clarithromycin in patients with suspected Gram-negative sepsis: results of a randomized controlled trial.
    Giamarellos-Bourboulis EJ; Mylona V; Antonopoulou A; Tsangaris I; Koutelidakis I; Marioli A; Raftogiannis M; Kopterides P; Lymberopoulou K; Mouktaroudi M; Papageorgiou C; Papaziogas B; Georgopoulou AP; Tsaganos T; Papadomichelakis E; Gogos C; Ladas M; Savva A; Pelekanou A; Baziaka F; Koutoukas P; Kanni T; Spyridaki A; Maniatis N; Pelekanos N; Kotsaki A; Vaki I; Douzinas EE; Koratzanis G; Armaganidis A
    J Antimicrob Chemother; 2014 Apr; 69(4):1111-8. PubMed ID: 24292991
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term survival and function after suspected gram-negative sepsis.
    Perl TM; Dvorak L; Hwang T; Wenzel RP
    JAMA; 1995 Jul; 274(4):338-45. PubMed ID: 7609265
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis.
    Rice TW; Wheeler AP; Bernard GR; Vincent JL; Angus DC; Aikawa N; Demeyer I; Sainati S; Amlot N; Cao C; Ii M; Matsuda H; Mouri K; Cohen J
    Crit Care Med; 2010 Aug; 38(8):1685-94. PubMed ID: 20562702
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of Ganciclovir on IL-6 Levels Among Cytomegalovirus-Seropositive Adults With Critical Illness: A Randomized Clinical Trial.
    Limaye AP; Stapleton RD; Peng L; Gunn SR; Kimball LE; Hyzy R; Exline MC; Files DC; Morris PE; Frankel SK; Mikkelsen ME; Hite D; Enfield KB; Steingrub J; O'Brien J; Parsons PE; Cuschieri J; Wunderink RG; Hotchkin DL; Chen YQ; Rubenfeld GD; Boeckh M
    JAMA; 2017 Aug; 318(8):731-740. PubMed ID: 28829877
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase 2 trial of eritoran tetrasodium (E5564), a toll-like receptor 4 antagonist, in patients with severe sepsis.
    Tidswell M; Tillis W; Larosa SP; Lynn M; Wittek AE; Kao R; Wheeler J; Gogate J; Opal SM;
    Crit Care Med; 2010 Jan; 38(1):72-83. PubMed ID: 19661804
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An evaluation of the hemodynamic effects of HA-1A human monoclonal antibody.
    Kett DH; Quartin AA; Sprung CL; Fisher CJ; Peña MA; Heard SO; Zimmerman JL; Albertson TE; Panacek EA; Eidelman LA
    Crit Care Med; 1994 Aug; 22(8):1227-34. PubMed ID: 8045141
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Phase II study of edobacomab (E5) in the treatment of gram-negative sepsis].
    Kobayashi H; Kawai S; Sakayori S; Kaneko M; Ito Y; Ujike Y; Kobayashi K; Imaizumi H; Hoshi S; Endo S
    Kansenshogaku Zasshi; 1994 Jan; 68(1):81-115. PubMed ID: 8138682
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of severe systemic inflammatory response syndrome and sepsis with a novel bradykinin antagonist, deltibant (CP-0127). Results of a randomized, double-blind, placebo-controlled trial. CP-0127 SIRS and Sepsis Study Group.
    Fein AM; Bernard GR; Criner GJ; Fletcher EC; Good JT; Knaus WA; Levy H; Matuschak GM; Shanies HM; Taylor RW; Rodell TC
    JAMA; 1997 Feb; 277(6):482-7. PubMed ID: 9020273
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Phase I study of edobacomab (E5) in patients with gram-negative sepsis].
    Kobayashi H; Kawai S; Sakayori S; Endo S; Hoshi S; Inada K; Yoshida M
    Kansenshogaku Zasshi; 1994 Jan; 68(1):59-80. PubMed ID: 8138680
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multicenter, double-blind, placebo-controlled study of the use of filgrastim in patients hospitalized with pneumonia and severe sepsis.
    Root RK; Lodato RF; Patrick W; Cade JF; Fotheringham N; Milwee S; Vincent JL; Torres A; Rello J; Nelson S;
    Crit Care Med; 2003 Feb; 31(2):367-73. PubMed ID: 12576938
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial.
    ; Armstrong PW; Granger CB; Adams PX; Hamm C; Holmes D; O'Neill WW; Todaro TG; Vahanian A; Van de Werf F
    JAMA; 2007 Jan; 297(1):43-51. PubMed ID: 17200474
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial.
    Opal SM; Laterre PF; Francois B; LaRosa SP; Angus DC; Mira JP; Wittebole X; Dugernier T; Perrotin D; Tidswell M; Jauregui L; Krell K; Pachl J; Takahashi T; Peckelsen C; Cordasco E; Chang CS; Oeyen S; Aikawa N; Maruyama T; Schein R; Kalil AC; Van Nuffelen M; Lynn M; Rossignol DP; Gogate J; Roberts MB; Wheeler JL; Vincent JL;
    JAMA; 2013 Mar; 309(11):1154-62. PubMed ID: 23512062
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of LY315920Na/S-5920, a selective inhibitor of 14-kDa group IIA secretory phospholipase A2, in patients with suspected sepsis and organ failure.
    Abraham E; Naum C; Bandi V; Gervich D; Lowry SF; Wunderink R; Schein RM; Macias W; Skerjanec S; Dmitrienko A; Farid N; Forgue ST; Jiang F
    Crit Care Med; 2003 Mar; 31(3):718-28. PubMed ID: 12626975
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of Sodium Selenite Administration and Procalcitonin-Guided Therapy on Mortality in Patients With Severe Sepsis or Septic Shock: A Randomized Clinical Trial.
    Bloos F; Trips E; Nierhaus A; Briegel J; Heyland DK; Jaschinski U; Moerer O; Weyland A; Marx G; Gründling M; Kluge S; Kaufmann I; Ott K; Quintel M; Jelschen F; Meybohm P; Rademacher S; Meier-Hellmann A; Utzolino S; Kaisers UX; Putensen C; Elke G; Ragaller M; Gerlach H; Ludewig K; Kiehntopf M; Bogatsch H; Engel C; Brunkhorst FM; Loeffler M; Reinhart K;
    JAMA Intern Med; 2016 Sep; 176(9):1266-76. PubMed ID: 27428731
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of immunomodulator therapy in sepsis.
    Caplan ES
    Am J Surg; 1993 Feb; 165(2A Suppl):20S-25S. PubMed ID: 8438996
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.